柴胡疏肝散治疗高原地区亚急性甲状腺炎

目的:观察柴胡疏肝散治疗高原地区亚急性甲状腺炎(SAT)的疗效。方法:将纳入研究的116例患者依据纳入顺序单双号随机分为治疗组和对照组,各58例。对照组给予常规西医治疗,治疗组在对照组治疗的基础上给予柴胡疏肝散。治疗1个月观察疗效,随访半年观察复发情况。结果:治疗1个月,治疗组总有效率96.55%,对照组总有效率81.03%,两组比较有显著性差异(P0.05);治疗组游离T3(FT3),FT4,C反应蛋白(CRP),血沉下降明显,促甲状腺激素(TSH)显著上升,与对照组比较均有显著性差异(P0.05);随访半年后治疗组复发5例,复发率8.62%,对照组复发26例,复发率44.83%,两组复发率比较有显著性差异(P0.05);两组均无不良反应发生。结论:柴胡疏肝散配合西药治疗亚急性甲状腺炎疗效确切,可显著降低复发率,临床值得推广。

Clinical Observation of Chaihu Shugan San in Treatment of Subacute Thyroiditis Plateau

Objective: The purpose of this study was to observe the efficacy of Chaihu Shugan San(CHSGS) in the treatment of subacute thyroiditis in plateau area. Method: In this study, one hundred and sixteen cases of patients were included and randomly divided into the traditional Chinese medicine (TCM) group and the western medicine group by odd and even numbers, with 58 cases in each group. The patients in the Western medicine group were treated with conventional western medicine, and the patients in the TCM group were given CHSGS on the basis of conventional western medicine. The efficacy was observed after treatment, and the recurrence were observed in the following six months. Result: After one month, the total efficiency in the TCM group was 96.55%, while it was 81.03% in the western medicine group, and the difference was statistically significant (P<0.05). The FT3,FT4,C-reactive protein(CRP), ESR in the TCM group decreased significantly, and thyroid stimulating hormone(TSH) was increased and the difference was statistically significant compared with the Western medicine group(P<0.05). In the TCM group, there were 5 recurrence cases after six months, and the recurrence rate was 8.62%, while in the western medicine group there were 26 recurrence cases with a recurrence rate of 44.83%, the difference between two groups was statistically significant (P<0.05).There was no adverse reaction in both two groups. Conclusion: CHSGS combined with the western medicine was curative in the treatment of subacute thyroiditis, which can significantly reduce the relapse rate, and be worth of promoting in clinical.